Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)

SIMPLE SUMMARY: High-dose therapy with melphalan followed by autologous stem cell transplantation and lenalidomide maintenance has long been the standard of care for newly diagnosed patients with multiple myeloma. However, it is unclear how lenalidomide dosage or experienced side effects govern pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Boquoi, Amelie, Giagounidis, Aristoteles, Goldschmidt, Hartmut, Heinsch, Michael, Rummel, Mathias J., Kröger, Nicolaus, Mai, Elias K., Strapatsas, Judith, Haas, Rainer, Kobbe, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650513/
https://www.ncbi.nlm.nih.gov/pubmed/37958331
http://dx.doi.org/10.3390/cancers15215157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650513/
https://www.ncbi.nlm.nih.gov/pubmed/37958331
http://dx.doi.org/10.3390/cancers15215157

Ejemplares similares